Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Complete androgen blockade versus monotherapy]

J E Altwein1

  • 1Urologische Abteilung, Krankenhaus der Barmherzigen Brüder, München-Nymphenburg.

Der Urologe. Ausg. A
|May 1, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unusually large numbers needed to treat for radical prostatectomy in prostate cancer patients with PSA velocity ≤2 ng/ml/year.

Urologia internationalis·2012
Same author

[LHRH analogues for the treatment of prostate cancer: an evidence level-based analysis].

Aktuelle Urologie·2009
Same author

[Primary prevention of bladder cancer. What's new?].

Der Urologe. Ausg. A·2007
Same author

[Local recurrence of prostate cancer: hormone therapy].

Der Urologe. Ausg. A·2006
Same author

Biphosphonates in advanced prostate and renal cell cancer--current status and potential applications.

Urologia internationalis·2006
Same author

[Fortuitous finding microhematuria].

MMW Fortschritte der Medizin·2005
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
See all related articles

Maximal androgen deprivation (MAD) is not superior to partial androgen deprivation, and thus not a new gold standard. Patient involvement is crucial for treatment decisions due to unclear prognostic factors.

Area of Science:

  • Oncology
  • Urology

Context:

  • Androgen deprivation therapy (ADT) is a cornerstone in advanced prostate cancer treatment.
  • Maximal androgen deprivation (MAD) and partial androgen deprivation (PAD) are treatment strategies.
  • Quality of life (QoL) is a critical consideration in palliative cancer care.

Purpose:

  • To compare the efficacy of maximal androgen deprivation (MAD) versus partial androgen deprivation (PAD) in advanced prostate cancer.
  • To evaluate the impact of ADT on quality of life in palliative cancer care.
  • To determine the role of MAD as a potential new gold standard in prostate cancer treatment.

Summary:

  • A meta-analysis of 29 studies found no significant superiority of MAD over PAD.
  • MAD cannot be considered the new gold standard for advanced prostate cancer.

Related Experiment Videos

  • The flare phenomenon necessitates initiating MAD in patients with advanced bone metastasis or severe pain.
  • Quality of life, a key palliative aim, requires further evaluation, particularly in large multicenter studies like intergroup study 0105.
  • Synergistic effects of LHRH agonists on the prostate are under investigation.
  • Lack of clear prognostic factors and PSA reduction not delaying progression underscore the need for shared decision-making between patient and physician regarding MAD initiation.

    • Impact:

    • Findings challenge the established hierarchy of ADT strategies.
    • Highlights the importance of patient-centered care and shared decision-making in oncology.
    • Emphasizes the need for further research into QoL outcomes in advanced prostate cancer patients undergoing ADT.